ERBB2 and breast cancer: In multivariate analysis, HER2+ (versus HER2-) status was associated with poor BC-SS for non-T4 patient cases (hazards ratio = 1.16, 95% CI = 1.05 to 1.28), had no association with BC-SS for LABC patient cases (hazards ratio = 0.96, 95% CI = 0.72 to 1.28) or MBC patient cases (hazards ratio = 0.95, 95% CI = 0.82 to 1.11), and had a borderline significant association with improved BC-SS for IBC patient cases (hazards ratio = 0.82, 95% CI = 0.68 to 0.99) after adjustment for age, race, grade, SES, surgery, radiation therapy, and chemotherapy (Table 4).